What records are connected here?
- Evidence lanes
- 3
- Source years
- 3
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Smaller human trialsHormones · Bone and growth
Palopegteriparatide is a long-acting prodrug of teriparatide, the active first 34 amino acids of human parathyroid hormone, and the active ingredient in Yorvipath.1,2 FDA approved Yorvipath in 2024 for hypoparathyroidism in adults, a condition in which the body makes too little parathyroid hormone and blood calcium runs low.1,2 In a 26-week randomized, placebo-controlled trial of 82 adults, 69% on palopegteriparatide kept normal blood calcium without conventional calcium and active vitamin D therapy, versus 5% on placebo.1
| What it is | A parathyroid hormone analogue: PTH(1-34) attached to an inert carrier by a linker that releases it steadily in the body, according to the label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Yorvipath with an original approval date of August 9, 2024. The cited label has no boxed warning.1,2 |
| Human evidence | One 26-week randomized, double-blind, placebo-controlled Phase 3 trial in 82 adults with hypoparathyroidism, described in the label.1 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Palopegteriparatide is a prodrug of teriparatide, PTH(1-34), the 34 amino acids at the start of the 84-amino-acid human parathyroid hormone, joined to an inert carrier through a TransCon linker.1
In the United States it is the active ingredient of Yorvipath, from Ascendis Pharma, according to Drugs@FDA.2
The label states that under the body’s conditions it releases PTH(1-34) to maintain continuous exposure.1
Parathyroid hormone raises blood calcium and lowers phosphate by acting on bone, helping the kidneys keep calcium, and promoting active vitamin D, according to the label.1
The label describes a 26-week randomized, double-blind, placebo-controlled trial in 82 adults with hypoparathyroidism, 85% of whom had lost parathyroid function after neck surgery; 61 received palopegteriparatide and 21 placebo.1
The main outcome combined normal blood calcium with independence from active vitamin D and high-level calcium supplements. It was met by 68.9% on palopegteriparatide and 4.8% on placebo, according to the label.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Yes. Drugs@FDA lists Yorvipath, application NDA 216490, with an original approval date of August 9, 2024.2
The Yorvipath label cited here (DailyMed SPL version 10, published November 9, 2026) states that it is indicated for the treatment of hypoparathyroidism in adults, and that it was not studied for sudden hypoparathyroidism right after surgery.1
The label has no boxed warning. Its warnings include allergic reactions, serious high and low blood calcium, a potential risk of osteosarcoma (a bone cancer), and falls in blood pressure on standing.1
Its effects beyond the 26-week controlled period described in the label’s trial.1
Its use in acute hypoparathyroidism after surgery, which the label states was not studied.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Palopegteriparatide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Palopegteriparatide are a bounded selection, not every registration or paper about Palopegteriparatide. For the years before Palopegteriparatide was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Palopegteriparatide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Palopegteriparatide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Yorvipath for hypoparathyroidism in adults. A 26-week randomized, placebo-controlled trial of 82 adults described in the label found that most patients kept normal blood calcium without conventional therapy. The label warns of a potential risk of osteosarcoma.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Yorvipath for hypoparathyroidism in adults. A 26-week randomized, placebo-controlled trial of 82 adults described in the label found that most patients kept normal blood calcium without conventional therapy. The label warns of a potential risk of osteosarcoma.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date November 5, 2026
ClinicalTrials.gov record NCT07081997↗Added to PeptideScanner November 15, 2026Clinical trials · added November 15, 2026
ClinicalTrials.gov record NCT07081997↗Source date November 5, 2026Literature metadata · added November 15, 2026
Palopegteriparatide: Parathyroid Hormone Analog for the Treatment of Chronic Hypoparathyroidism in Adults.↗Source date October 24, 2026Literature metadata · added November 15, 2026
Discontinuation of palopegteriparatide in chronic hypoparathyroidism without rebound hypocalcemia.↗Source date October 15, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
2 of 4 selected trial records include at least one phase value; 4 of 4 include a status value in the retained structured contract.
A phase value is unavailable here for 2 selected records; this is not counted as “no phase.”
9 of 9 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT07081997 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was palopegteriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT07264634 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was palopegteriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT07345494 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was palopegteriparatide.
9 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span August 9, 2024 to November 5, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07081997 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was palopegteriparatide.↗
Literature metadata
PubMed lists PMID 42924498 in The Annals of pharmacotherapy as Journal Article, Review, with publication-date metadata of 2026-10-23 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42871663 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-10-13 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42789535 in European journal of endocrinology as Journal Article, Case Reports, with publication-date metadata of 2026-10-05 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41636590 in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2026-09-24 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42139093 in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research as Journal Article, with publication-date metadata of 2026-09-24 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42614145 in JBMR plus as Case Reports, Journal Article, with publication-date metadata of 2026-07-21 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42440695 in Journal of the Endocrine Society as Journal Article, with publication-date metadata of 2026-04-18 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07264634 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was palopegteriparatide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07706764 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was palopegteriparatide.↗
Regulatory
The Federal Register published notice 2026-10277, attributed to FDA and its parent HHS department, on 2026-05-22. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Palopegteriparatide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07345494 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was palopegteriparatide.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026